Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

Abstract

ABT-263 demonstrated in vitro activity against a range of cell lines, with the ALL cell lines showing the greatest sensitivity. ABT-263 demonstrated limited single agent in vivo activity against the PPTP's solid tumor panels but showed significant activity against xenografts in the ALL panel.